T lymphocytes respond to antigenic peptides presented on major MHC molecules. Cytotoxic CD8 ϩ T cells recognize peptides in the context of MHC class I, whereas CD4 ϩ Th cells recognize peptides in complex with MHC class II. Naive T cell activation is restricted to secondary lymphoid organs, such as the spleen and LNs, and is thought to rely on specialized " professional " APCs comprising B cells, macrophages, and DCs. The APC composition of lymphoid organs likely encodes a potential to initiate distinct T cell responses. However, the diff erential contribution of APC to in vivo immune responses remains poorly understood.
Natural IFN-producing cells (IPCs) are a unique subset of hematopoetic cells that play a critical role in the innate and adaptive immune defense against infections ( 1 ) . Viruses (or unmethylated CpG DNA) engage Toll-like receptor (TLR) 7 and 9 on IPCs ( 2 ) and trigger the secretion of massive amounts of type I interferons (IFN-␣ , -␤ , -, and -) ( 3 ). This specialization of IPCs in cytokine production is refl ected in their distinct " plasmacytoid " morphology, resembling Ig-secreting plasma cells ( 4 ) . IPC-derived cytokines are critical for the initiation of early antiviral NK cell responses ( 5, 6 ) . In addition, IPC-derived type I IFNs boost the ability of conventional DCs (cDCs) to mature and stimulate T cells, thus, promoting antiviral CTL responses ( 7, 8 ) . Furthermore, IPCs provide a critical costimulatory signal for the CpG-induced activation of cDCs ( 9, 10 ) . Independent of their cytokine-and CD40L-mediated accessory function to control NK and cDC activities, IPCs have also been proposed to play a direct role as APCs in the onset of T cell stimulation. The constitutive presence of IPCs in lymphoid organs, their expression of MHC molecules, and their acquisition of DC morphology upon culture, has led to the idea that IPCs represent a distinct DC subset, the so-called plasmacytoid DCs (PDCs). However, the original discovery of DCs defi ned them by the capacity to prime naive T cells ( 11 ) , and this activity has remained their hallmark. Moreover, recent in vivo DC depletion experiments indicate that CD11c high cDCs are required to initiate cytotoxic CD8 ϩ T cell responses against intracellular pathogens ( 12, 13 ) . The potential of IPC/PDCs to prime naive T cells, however, remains controversial. Freshly isolated PDCs are generally poor T cell stimulators. Thus, human blood -derived PDCs do not stimulate naive CD4 + T cells in a MLR, unless cultured in the presence of IL-3 or virus (HSV) ( 14 ) . Moreover, murine splenic PDCs fail to induce naive T cell proliferation to endogenous antigens, even after virus exposure ( 15 ) . In contrast, murine peptide-pulsed PDCs derived from Flt-3 -driven BM culture or spleens can promote the in vitro expansion of CD4 ϩ T cells and Th cell polarization ( 16 ) . Adoptive transfer experiments with splenic and BM culture -derived, CpG-matured PDCs showed that PDCs can elicit responses of naive CD8 ϩ T cells to endogenous, but not exogenous, antigens ( 17 ) . These confl icting results are likely caused by the diff erent source of the PDCs used in the reports. Moreover, none of the studies addressed the in vivo potential of unmanipulated PDCs to prime naive T cells.
Recently, IPC/PDCs have been shown to play a critical role in the control of airway infl ammation ( 18, 19 ) and allotransplant rejection ( 20, 21 ) . Although these fi ndings mark PDCs as potential candidates for future adoptive cell therapies, such approaches will require better understanding of the in vivo characteristics of this unique cell type.
We analyze CD4 ϩ and CD8 ϩ T cell responses to antigen challenge in mice that were conditionally depleted of CD11c high cDCs, but retain IPC/PDCs. We show that depletion of cDCs impairs splenic T cell responses, indicating that PDCs are incapable of T cell priming in this organ. In contrast, the combined use of cDC ablation and a novel PDC-specifi c antigen-targeting strategy revealed that, in LNs, PDCs can effi ciently trigger productive naive CD4 ϩ T cell responses. Interestingly, and in contrast to cDC-driven responses, the PDC-triggered CD4 ϩ T cell stimulations lack a concomitant CD8 ϩ T cell expansion. Our in vivo results, thus, characterize PDCs as bona fi de DCs that can initiate unique CD4 ϩ Th cell -dominated primary immune responses.
RESULTS

PDCs are spared from ablation in DTx-treated CD11c-DTR transgenic mice
To investigate diff erential in vivo functions of APCs in lymphoid organs, we recently developed a diphtheria toxin receptor (DTR) -based system that allows the conditional ablation of CD11c high cDCs ( 12 ) . DTR expression in CD11c-DTR transgenic mice is driven by a DNA fragment fl anking the (E) IFN-␣ production by splenic PDC and non-PDC cell fractions isolated from noninjected or DTx-injected CD11c-DTRtg mice and incubated in vitro for 20 h in the presence or absence of 400 HAU/ml influenza virus and blood sera analysis of DTx-treated and untreated CD11c-DTRtg mice, 6 h after PBS or 100 g CpG i.v. injection. Error bars depict the SD. mice a small fraction of mPDCA-1 ϩ 440c ϩ CD11c low cells that were DTR/GFP ϩ and DTx sensitive; however, upon in vitro exposure to virus, these cells did not secrete IFN-␣ ( Fig. 1, B 
PDCs fail to prime naive T cells in the spleen
We fi rst investigated the potential of splenic PDCs to stimulate naive T cells in the absence of CD11c high cDCs. We isolated TCR transgenic OVA-specifi c CD8 ϩ and CD4 ϩ T cells from OT-I and -II mice, respectively ( 34, 35 ) . Donor mice carried an allotypic marker (CD45.1) that allowed for detection of the transferred cells in the recipient mice. Before transfer, the T cells were labeled with the intracellular dye CFSE, which allows the monitoring of in vivo proliferation ( 36 ) . T cells were cotransferred into WT and CD11c-DTR transgenic C57BL/6 mice. The grafted mice were treated with DTx and, 8 h later, immunized by i.v. injection of soluble OVA (10 g) or OVAloaded splenocytes ( 37 ). 4 d after immunization, the mice were killed and spleens were isolated and analyzed for the proliferation status of the T cell grafts ( Fig. 2 ) . All challenges resulted in vigorous expansion of both CD4 ϩ and CD8 ϩ T cell grafts in the WT recipient mice. As previously reported ( 12 ) , depletion of CD11c high cDCs impaired the response of CD8 ϩ T cells to cell-associated antigen. Presentation of antigen in the context of MHC class I to CD8 ϩ T cells requires a unique phagosometo-cytosol pathway resulting in cross-presentation, which is an activity proposed to be uniquely associated with cDCs or cDC subsets ( 12, 37, 38 ) . In support of this notion, we found that cDCs are also needed for CD8 ϩ T cell priming after challenge with exogenous soluble antigen ( Fig. 2 ) . Moreover, depletion of splenic cDCs also abrogated OVA-specifi c CD4 ϩ T cell responses to cell-associated and soluble antigen, thus extending the study by Tian et al. ( 39 ) . Importantly, as opposed to a recent study ( 40 ) , we evaluated the T cell -priming potential of PDCs in the absence of cDCs. Splenic PDCs are unable to prime naive CD4 ϩ and CD8 ϩ T cells in the absence of CD11c high cDCs.
PDCs can prime naive CD4 ؉ T cells in LNs, but fail to support CD8 ؉ T cell priming T cell responses are initiated in specialized secondary lymphoid organs, such as the spleen and LNs, which diff er considerably in their microarchitecture, refl ecting their specialization for the handling of blood-and tissue-borne antigens, respectively. We next investigated whether CD11c high DCs would also be required in the LNs. Local, s.c. DTx injection results in the rapid depletion of LN-resident cells expressing the DTR-GFP fusion protein, including both CD8 ␣ ϩ and CD8 ␣ -CD11c high cDCs and sinusoidal macrophages ( 23 ), but not PDCs ( Fig. 1 C ;  Fig. 3 A ; Fig. S1 , A -C). Repetitive s.c. DTx injection results in persistent cDC ablation ( Fig. 3 A and Fig. S2 A, available at Itgax gene ( 22 ) , which encodes the ␣ X subunit of the CD11c integrin. Murine CD11c expression is found in all cDCs, but has also been reported for certain macrophages ( 23 -25 ) , activated T cells ( 26 ) , NK cells ( 27 ) , and plasmablasts ( 28 ) .
Murine PDCs are defi ned as being CD11c low B220 ϩ Ly6C ϩ , and, furthermore, can be identifi ed by the PDCspecifi c antibodies 120G8 ( 29 ) , 440c ( 30 ) , and mPDCA-1 ( 31 ) . To test the DTx sensitivity of CD11c-DTR transgenic CD11c low PDCs, we injected CD11c-DTR transgenic C57BL/6 mice with DTx. Flow cytometric analysis of the spleens 1 d after DTx treatment revealed that PDCs were spared from DTx-induced ablation, whereas cDCs were depleted ( Fig. 1 A and Fig. S1 A, available at http://www.jem.org/cgi/content/ full/jem.20062373/DC1). The DTx resistance of PDCs is explained by the absence of expression of the DTR-GFP fusion protein by the bulk population of these cells ( Fig. 1 B ) . Moreover, it was also confi rmed for LN PDCs ( ( 22 ) does not carry all transcription control elements required for physiological ␣ X subunit expression in CD11c ϩ cells ( 32 ) , and further supports the notion that PDCs and cDCs are genetically distinct entities ( 33 ) . To investigate whether the toxin treatment results in a functional impairment of PDCs, we tested type I interferon responses. As seen in Fig. 1 E , DTx treatment neither aff ected the IFN-␣ response to in vivo CpG treatment nor compromised the ability of PDCs to produce IFN-␣ in response to an in vitro infl uenza virus challenge. Notably, we consistently observed in spleens, but not LNs, of CD11c-DTR transgenic C57BL/6 OVA ( Fig. 3 B ) . Importantly, the DTx-induced cDC depletion abrogated the expansion of CD8 ϩ T cells, indicating that, as in the spleen, priming of naive CD8 ϩ T cells required the presence of cDCs. Surprisingly, however, we observed a proliferative response of the grafted CD4 ϩ T cells in the cDC-depleted LNs ( Fig. 3 B ) . Importantly, this was unlikely to be caused by residual cDCs because the DTx treatment impaired in the same LNs the CD8 ϩ T cell response, which is generally more sensitive to antigen challenge ( 41 ) . The persistence of the CD4 ϩ T cell priming in the absence of cDCs was also observed in CD11c-DTRtg BALB/c mice, in combination with an OVA-specifi c TCR transgenic naive CD4 ϩ T cell graft isolated from DO11.10 mice (Fig. S3 ) ( 42 ) . Moreover, to confi rm our observation in a non-TCR transgenic system and with an antigen other than OVA, we challenged untreated and cDC-depleted DTRtg mice with KLH/CpG and analyzed the resulting response of endogenous CD4 ϩ T cells. 7 d after s.c. antigen challenge, we purifi ed CD4 ϩ T cells from popliteal LNs and subjected them to an in vitro restimulation protocol with KLH-pulsed APC. Again, CD4 ϩ T cells were effi ciently primed irrespective of the presence of cDCs (Fig. S2 ).
Our data show that LNs contain APCs other than CD11c high DCs or macrophages that are capable of stimulating naive CD4 ϩ T cells. Although PDCs are potential candidates, other MHC class II ϩ cells could be responsible for the CD4 ϩ T cell priming. By far, the largest MHC class II ϩ population in the LNs are B lymphocytes, which, even when naive, have been shown to effi ciently ingest and process noncognate protein antigens ( 43 ) . However, the ability of B cells to activate naive CD4 ϩ T cells remains under debate ( 44 -46 ) . Moreover, pMHC encounter on B cells is believed to result in nonproductive T cell priming or tolerization ( 47 ) . To investigate the role of B cells in our system, we crossed the CD11c-DTR transgene onto a B cell -defi cient genetic background (C57BL/10-Igh-6tm1Cgn [ MT]) ( 48 ) . CD11c-DTRtg: MT and MT C57BL/6 mice were engrafted with OVA-specifi c http://www.jem.org/cgi/content/full/jem.20062373/DC1). To investigate the impact of the LN cDC depletion on T cell responses in this organ, we engrafted WT and CD11c-DTR transgenic C57BL/6 recipient mice with a mixture of OVAspecifi c CD4 ϩ (OT-II) and CD8 ϩ T cells (OT-I). The mice were subjected to the DTx treatment (which was continued throughout the experiment to maintain cDC depletion; ( Fig. S4 C) . Collectively, these data suggest that cells other than cDCs, macrophages, B cells, or LCs are responsible for the priming of CD4 ϩ T cells, and point at a role for PDCs in antigen presentation.
LN PDCs effi ciently acquire and process soluble antigen and prime productive T cell responses Antigen presentation and CD4 ϩ T cell priming by LNresident PDCs would require their antigen uptake. Importantly, soluble antigens of low molecular weight ( < 70 kD) are readily transported into the T cell zone of the LN, i.e., PDC proximity, via a highly developed conduit network ( 51 ) . To investigate whether LN PDCs have access to antigen, we immunized C57BL/6 WT mice with DQ-OVA and analyzed LN APC populations for antigen uptake. This fl uorogenic reagent is undetectable in its unprocessed form because of autoquenching, but becomes fl uorescent upon entry into acidic, endosomal cellular compartment. As seen in Fig. 4 , DQ-OVA was readily ingested by the LN-resident CD11c high DCs and subjected to processing as indicated by the induction of the green fl uorescent label. PDCs were labeled at least as effi ciently as CD11c high cDCs, whereas B cells remained CD4 ϩ T cells (OT-II) and subjected to the DTx treatment and OVA immunization. B cell defi ciency resulted in a reduced recovery of grafted CD4 ϩ T cells in DTx-treated CD11c-DTRtg: MT and MT C57BL/6 mice. However, the frequency of OT-II cells that lost the CFSE-label, and thus proliferated in response to the OVA challenge, was unaff ected by the absence of B cells (Fig. S4, A ( 49 ) . LCs would, hence, be expected to become DTx sensitive by the time they reach the LNs. To nevertheless exclude the possibility that the CD4 ϩ T cell response we observed was caused by residual LCs, we crossed the CD11c-DTR transgenic mice to mice that harbor the DTR gene under the LCspecifi c Langerin promoter ( 50 ) . DTx-treatment of LanDTR: CD11cDTR mice results in ablation of cDCs and LCs (unpublished data). However, the response of the adoptively transferred OT-II CD4 ϩ T cells to the OVA challenge persisted 
PDC-specifi c antigen targeting and PDC-mediated in vivo and in vitro CD4 ؉ T cell priming
The aforementioned results suggest that LN PDCs effi ciently ingest exogenous antigen and are able to initiate productive CD4 ϩ T cell responses. To obtain independent evidence that PDCs can act as APCs, we decided to adopt a strategy involving specifi c, antibody-mediated, antigen-targeting APCs ( 53 ) and conjugate the PDC-specifi c mPDCA-1 antibody to OVA. To avoid complement-dependent lysis ( 31 ), we used a nondepleting F(ab ' ) 2 fragment. Functional integrity of the construct was tested by Western blotting. As depicted in Fig. 6 A , the conjugates were readily detected both via the kappa light chain and the OVA-fraction, whereas free OVA or unconjugated mPDCA-1 -F(ab ' ) 2 fragments were only detected with the anti-rat IgG or the -OVA antibody, respectively. The OVAconjugated antibody fragment specifi cally targeted PDC in splenic or LN single-cell suspensions in vitro (unpublished data). To demonstrate in vivo specifi city, we took advantage of a FITC conjugate of the mPDCA-1 -F(ab ' ) 2 -OVA construct. Intravenous or s.c. injection of FITC -mPDCA-1 -F(ab ' ) 2 -OVA resulted in specifi c labeling of CD11c low PDCs in spleens and LNs and spared CD11c high cDCs ( Fig. 6 B ) .
To direct the OVA antigen to both PDCs and cDCs, we used the mPDCA-1 -F(ab ' ) 2 -OVA conjugate (mPDCA-1 -OVA) and an OVA conjugate that targets a subset of CD11c high cDCs via the CD205 receptor (DEC205 -OVA) ( 53, 59 ) . We fi rst investigated the response of OVA-specifi c CD8 ϩ T cells (OT-I) to the conjugate challenge. As seen in Fig. 7 A , s.c. immunization of untreated CD11c-DTRtg mice with the mPDCA-1 -OVA and DEC205 -OVA conjugates resulted in comparable responses of the naive CD8 ϩ T cells in the draining popliteal LNs. Importantly, depletion of cDCs abrogated both the DEC205 -OVA and the mPDCA-1 -OVA -induced CD8 ϩ T cell expansion. Thus, the cDC-driven unaff ected by the DQ-OVA challenge. Importantly, as it occurred in naive mice, antigen uptake was independent of anti-OVA antibodies, and hence Fc ␥ receptors, which have been implied in PDC antigen capture ( 52 ) . Thus, PDCs have access to antigen in our experimental system, and they could be responsible for the priming of CD4 ϩ T cells in LNs depleted of the CD11c high DCs.
Proliferative T cell expansion can be associated with the generation of cytokine-producing eff ector T cells, but also abortive T cell responses ( 53 -55 ) . We therefore investigated the quality of the primed LN CD4 ϩ T cells by studying Th cell polarization and long-term T cell survival. To analyze Th cell polarization of the grafted OVA-specifi c CD4 ϩ T cells, we performed an in vivo restimulation assay by rechallenging the OVA-immunized mice with an i.v. injection of OVA peptide ( 56 ) . Both in the presence and absence of CD11c high cDC, CD4 ϩ T cells diff erentiated effi ciently into IFN-␥ -producing eff ector T cells ( Fig. 5 A ) . Abortive T cell stimulation is characterized by a collapse of the antigen-specifi c T cell population after its initial expansion ( 53, 54 ) . To test the persistence of CD4 ϩ T cells that were primed in the absence of cDCs, we used mixed CD11c-DTR BM chimeras, which allow for repetitive DTx treatment, and hence extended cDC depletion ( 57 ) . In both untreated and cDC-depleted mice, the OT-II CD4 ϩ T cell graft clonally expanded and persisted well beyond the initial antigen challenge ( Fig. 5 B ) . Furthermore, in both the presence and absence of cDCs, the grafted naive CD4 ϩ T cells diff erentiated into T cells of CD45RB low memory phenotype ( 58 ) . Collectively, PDCs seem capable of stimulating naive CD4 ϩ T cells, resulting in a persistent response that includes IFN-␥ -producing eff ector T cells of memory phenotype. Importantly, and in contrast to the immune reaction triggered by cDCs, this response is not accompanied by a concomitant CD8 ϩ T cell response. naive CD4 ϩ and CD8 ϩ T cells in the spleen is uniquely restricted to cDCs. Ablation of cDCs, however, revealed the surprising potential of PDCs to support CD4 ϩ T cell responses CD8 ϩ T cell response to the mPDCA-1 -OVA conjugate was likely caused by antibody-independent antigen uptake by cDCs or secondary cross-presentation of cellular PDC debris by cDCs. Conventional DC ablation revealed that, in contrast to a recent study ( 40 ) , even when directly targeted with exogenous antigen, PDCs seem unable to trigger CD8 ϩ T cell responses. Instead, our results support the notion of the general inability of PDCs to channel exogenous antigen into the MHC class I presentation pathway and cross-present ( 17 ) .
Next, we analyzed the response of OVA-specifi c LN CD4 ϩ T cells (OT-II) to conjugate challenge. Like the immunization with OVA, challenge of untreated CD11c-DTRtg mice with the antibody-conjugates resulted in vigorous expansion of the CD4 ϩ T cell grafts. In contrast to the CD8 ϩ T cell responses, and confi rming our previous results ( Fig. 3 ) , the CD4 ϩ T cell responses to the OVA and mPDCA-1 -F(ab ' ) 2 -OVA challenge resisted the DTx treatment in CD11c-DTR transgenic mice ( Fig. 7 B ) . Importantly, however, the CD4 ϩ T cell response to the DEC205 -OVA challenge was impaired by depletion of CD11c high cDCs. These results provide further evidence that the CD4 ϩ T cell response we observe in the absence of CD11c high cDCs is driven by PDCs. Notably, the antibodies to DEC205 and mPDCA-1 target distinct surface receptors ( 60, 61 ) , which likely diff er in their potential to promote endocytosis. This precludes any quantitative conclusion on the priming potential of cDCs versus PDCs.
To obtain fi nal proof for the CD4 ϩ T cell priming potential of PDCs, we decided to use an antibody-mediated depletion protocol to test T cell responses in the combined absence of both cDCs and PDCs. However, in our hands, even repetitive injection of mPDCA-1 and anti-Gr1 antibodies ( 18, 31 ) resulted in incomplete LN PDC depletion (unpublished data). Therefore, we resorted to an in vivo loading/in vitro readout system. WT BALB/c mice were immunized with OVA or mPDCA-1 -OVA. 1 d later, PDCs, cDCs, and B cells were isolated from LNs and spleens, sorted to purity, and tested in vitro for their ability to prime naive OVA-specifi c CD4 ϩ T cells (DO11.10). As seen in Fig. 8 , cDCs isolated from LNs or spleens of OVA-immunized mice readily stimulated T cell proliferation, whereas cDCs and B cells isolated from mPDCA-1 -OVA -immunized mice failed to do so. This confi rms the specifi city of the in vivo antigen-targeting strategy ( Fig. 6 B ) . Importantly, PDCs isolated from LNs of mice immunized with both OVA and mPDCA-1 -OVA were able to stimulate the naive CD4 ϩ T cells. Substantiating our in vivo data on the inability of splenic PDCs to prime CD4 ϩ T cells, in the in vitro assay PDCs isolated from spleens of immunized mice also failed to stimulate the T cells. Collectively, our results show that LN PDCs can initiate unique CD4 ϩ Th cell -dominated primary immune responses.
DISCUSSION
We analyzed the responses of naive CD4 ϩ and CD8 ϩ T cells to antigen challenge in mice that were depleted of conventional CD11c high cDCs, but retained PDCs. In support of previous reports ( 12, 39 ), we found that the capacity to prime Surprisingly, PDCs could prime CD4 ϩ T cells in the LNs, but not in cDC-depleted spleens. It remains unclear whether this discrepancy results from the distinct organ architecture or refl ects an inherent diff erence between splenic and LN PDCs. In support of the former, in naive mice PDCs are located in the red pulp and T cell area, but rarely in the marginal zone, which is the site of blood-borne antigen entry to the spleen ( 62 ) . Moreover, when challenged, splenic PDCs form clusters and, compared with cDCs, they show a delayed translocation to the T cell zone ( 62 ) . This migration might be critical for the spleen, whereas it may not be required in the LNs. Recruitment of PDCs to the LNs occurs via high endothelial venules (HEVs), and thus the cells enter directly into the T cell area ( 63 ) . Even before antigen-carrying DCs arrive from the periphery, resident LN APCs are known to take up soluble antigens ( 47 ) , which enter the deeper LNs through an intricate network of conduits ( 51 ) . Accessibility of antigen to LN PDCs is also highlighted by the observation that these cells readily ingested injected DQ-OVA ( Fig. 4 ) , although, interestingly, we failed to label splenic PDCs by intravenous DQ-OVA injection (not depicted). Alternatively, the unique ability of LN PDCs to prime CD4 ϩ T cells might indicate that these cells diff er from their splenic counterpart. Indeed, even when we targeted antigen directly to both LN and spleen PDCs and overrode the need for translocation (by an in vitro readout; Fig. 8 ), splenic PDCs failed to prime CD4 ϩ T cells ( Fig. 8 ) . Interestingly, LN PDCs are characterized by a distinct expression pattern of activation markers, such as Sca-1, and are poor producers of IFN-␣ compared with Sca-1 ϩ BM PDCs (unpublished data). However, a more detailed comparative study will be required to investigate qualitative diff erences between splenic and LN PDCs. Importantly, the antigen challenge results in a rapid PDC infl ux to the LN, and in our experimental setup, we do not discriminate between LN-resident and recruited PDCs.
Although we would like to stress that we do not want to compare the effi ciency of cDCs and PDCs in T cell priming potential, we establish that PDCs can prime naive CD4 ϩ T cells. Absence of cDCs is arguably an artifi cial situation unlikely to occur under physiological circumstances. However, we predict that pathogens that specifi cally target or activate PDCs will elicit exclusive CD4 ϩ T cell responses supporting humoral, but not cytotoxic, immunity. PDC-specifi c targeting could be mediated by endocytic receptors, such as Siglec-H ( 40, 64 ) , which are expressed on murine PDCs, but not cDCs. So far, murine PDC-specifi c pathogen sensors have not been reported, although PDCs are characterized by higher expression of TLR7 and TLR9 ( 65 ) , which are also expressed by human PDCs, but absent from human interstitial DCs ( 2, 66 ) . The unique priming of CD4 ϩ , but not CD8 ϩ , T cell responses by PDCs could result from exclusive presentation of exogenous antigens on MHC II, but not MHC I, molecules. As suggested earlier ( 17 ) , PDCs might lack the phagosome-to-cytosol pathway required for cross-presentation. Importantly, this would spare the priming PDCs from a unique negative-feedback mechanism through in the LNs. Importantly, PDCs diff ered from cDCs in that they could not induce CD8 ϩ T cell priming.
Naive T cells are stimulated in lymphoid organs by specialized, " professional " APCs that induce clonal T cell expansion and diff erentiation. Effi cient eradication of invading microbes requires distinct immune responses, involving both cellular and humoral defense mechanisms. Pathogen identification is believed to result from engagement of pathogen sensors (such as TLRs), which are diff erentially expressed on APCs and may allow distinct APC subsets to trigger specifi c responses. Division of labor between APCs, however, remains poorly understood. This is particularly true for IPC/ PDCs, which are critical for NK cells and cDC function, but whose in vivo capacity for antigen presentation and T cell priming remains unclear. We reasoned that any potential APC functions of PDCs might be masked by the presence of cDCs, and thus decided to test naive T cell responses in mice that were conditionally depleted of cDCs. F(ab ' ) 2 fragments were conjugated to OVA (Sigma-Aldrich) activated with succinimidyl 4-( N -maleimidomethyl) cyclohexane-1-carboxylate (Pierce Chemical Co.) according to the manufacturer ' s protocol. F(ab ' ) 2 -OVA conjugates were size fractionated and sterile fi ltrated (Millex GV fi lter unit 0.22 μ m; Millipore) for in vivo application. Construct integrity was evaluated by Western blot analysis with horseradish peroxidase -conjugated polyclonal rabbit anti -rat Ig (H+L; Jackson ImmunoResearch Laboratories) and horseradish peroxidase -coupled rabbit anti-OVA antibody (Research Diagnostics, Inc.), respectively. OVA content was determined by ELISA to be ‫ف‬ 75 ng OVA/ g mPDCA-1 F(ab ' ) 2 -OVA conjugate. To demonstrate in vivo specifi city, we injected 10 -25 μ g FITC-conjugated anti -mPDCA-1 -F(ab ' ) 2 -OVA i.v. or into the hind footpads. 3 h later, spleens or pooled popliteal and inguinal LNs were analyzed for PDC-specifi c targeting.
Immunohistochemistry. 4-m paraffi n sections of popliteal LNs were deparaffi nized and treated with 2 ml HCl, H 2 O 2 in 50% methanol, and 50% PBS for 15 min at room temperature. For antigen exposure, sections were microwaved in 10 mM sodium citrate, pH 6.0. After blocking with 20% heatinactivated normal goat serum and 0.1% Triton X-100 in PBS, sections were incubated overnight at room temperature with polyclonal biotinylated goat anti-GFP antibody (ab6658; Abcam). Staining was revealed with an avidinbiotin peroxidase complex (Vectastain Elite ABC kit; Vector Laboratories). Finally, the sections were stained with hematoxylin-Mayer (Finkelman).
Analysis of T cell proliferation. TCR transgenic T cells were isolated from spleens and LNs of respective mice, enriched by MACS cell sorting with anti-CD8 or -CD4 antibodies according to the manufacturer ' s protocol (Miltenyi Biotec GmbH), and labeled with CFSE (C-1157; Invitrogen) ( 57 ) . CFSE-labeled T cells (1 -2 × 10 6 /mouse) were injected into the tail veins of the recipient mice.
Immunization. Mice were immunized with cell-associated antigen by i.v. injection of 3 × 10 7 OVA-loaded ␤ 2m − / − splenocytes ( 37 ) . Soluble OVA (Sigma-Aldrich) was injected i.v. (10 g/mouse) or s.c. into hind footpads (10 g/footpad). KLH (Sigma-Aldrich) was injected s.c. into hind footpads (10 g/footpad). The anti -DEC205-OVA conjugate (provided by K. Mahnke, University Hospital Heidelberg, Heidelberg, Germany) was used at a dose of 7 ng/footpad. F(ab ' ) 2 and anti -mPDCA-1 -F(ab ' ) 2 -OVA were injected at a dose of 8 g/footpad. For measurement of Ag uptake, mice were immunized with DQ-OVA (Invitrogen) by hind footpad injection of 10 g/footpad.
Intracellular cytokine staining. Mice were immunized with 25 g OVA in 5 nmol/footpad CpG nucleotide 1668 (TIB MOLBIOL). 2 d later, mice were in vivo restimulated by intravenous injection of 100 g OVA peptide (residues 323 -329) 2 h before the removal of popliteal LNs. The tissue was minced and incubated in 1 mg/ml of collagenase D (Roche) for 20 min at 37 ° C in medium supplemented with 10 g/ml brefeldin A (Calbiochem). Cells were fi xed in 2% formaldehyde, permeabilized with 0.3% saponin, and stained for anti-CD45.1, -CD4, and -IFN-␥ antibodies.
Flow cytometric analysis. The staining reagents used in this study included the PE-coupled anti-CD4, CD19, CD45.1, CD11c, CD45RB, CD8, and KJ126 (DO11.10 clonotype); biotinylated anti-CD45.1 and mPDCA-1; APC-coupled CD11c, CD4, IFN-␥ , and CD8; the FITC-coupled anti-CD4; PE-Cy5.5 -coupled anti-B220 (Caltag Laboratories); and PerCP-coupled anti-CD4 and CD8 antibodies. Unless otherwise indicated, the reagents were obtained from PharMingen or eBioscience. The anti-Siglec-H antibody (440c) was provided by M. Colonna (Washington University School of Medicine, St. Louis, MO). Cells were analyzed on a cytometer (FACSCalibur; BD Biosciences) using CellQuest software (BD Biosciences).
Online supplemental material. Fig. S1 provides additional fl ow cytometric and histological data concerning the DTx sensitivity and resistance of cDCs and PDCs, respectively. Figs. S2 and S3 show unimpaired PDC-driven which CTLs kill APCs, and thereby terminate the priming process ( 67, 68 ) . The inability to cross-present would render PDCs resistant to the CTLs elicited by cDCs. In the course of an ongoing response to a given antigen, the APC balance might therefore be shifted from cDCs to PDCs and, as a result, priming of CD4 ϩ T cells and potentially humoral responses might be favored. As CD4 ϩ T cells also critically contribute to the development of CD8 ϩ T cell memory ( 69 ) , the APC function of PDCs might have a general impact on the shape of immune responses.
We show that in LNs, PDCs effi ciently trigger productive naive CD4 ϩ T cell responses. Interestingly, and in contrast to cDC-triggered responses, PDC-triggered CD4 ϩ T cell responses are not associated with concomitant CD8 ϩ T cell expansion. Instead, PDCs initiate unique CD4 ϩ Th celldominated primary immune responses.
MATERIALS AND METHODS
Mice. CD11c-DTR transgenic (B6.FVB-Tg Itgax-DTR/GFP 57Lan/J) mice ( 12 ); OT-I (C57BL/6) TCR transgenic mice harboring OVA-specifi c CD8 ϩ T cells ( 42 ); DO11.10 (BALB/c); and OT-II (C57BL/6) TCR transgenic mice harboring OVA-specifi c CD4 ϩ T cells ( 35 ) ; B cell -defi cient mice (C57BL/10-IgH-6tm1Cgn ( Mt) ( 48 ) and LanDTR mice carrying the DTR-GFP gene under the Langerin promoter ( 50 ) . LanDTR:CD11cDTR and DTRtg: MT mice were obtained by intercrossing of the respective lines. Mixed (DTR > WT) BM chimeras were generated as previously reported ( 57 ) . For systemic cDC depletion, mice were injected i.p. with 4 ng/g body weight DTx (D-2918; Sigma-Aldrich). For local cDC depletion in popliteal LNs, animals were injected with 20 ng DTx s.c. into hind footpads. If indicated, DTx was applied. All mice were used at the age of 6 -12 wk, maintained under specifi c pathogen-free conditions, and handled according to protocols approved by the Weizmann Institute Animal Care Committee as per international guidelines.
Isolation of CD11c high DCs and PDCs. Peripheral LNs or spleens were digested with 1 mg/ml of collagenase D (Roche) for 45 min at 37 ° C. Tissues were mechanically disrupted in PBS, and for spleens, RBC lysis was performed by incubation with 1 ml ACK buff er (0.15 M NH 4 Cl, 0.1 M KHCO 3 , 1 mM EDTA, and PBS) for 1 min at room temperature. PDCs were enriched by MACS cell sorting according to the manufacturer ' s protocol (Miltenyi Biotec GmbH).
In vitro proliferation assay. BALB/c mice were immunized i.v. (20 g OVA or 10 g mPDCA-1 -OVA) and s.c. into hind footpads (10 g OVA or mPDCA-1 -OVA). 24 h later, spleens and popliteal and inguinal LNs were harvested, and cDCs and PDCs were purifi ed by high-speed cell sorting according to CD11c and mPDCA-1 expression using a FACS Aria (Becton-Dickinson). Positive fraction of PDCs contained < 0.01% contaminating CD11c high cDCs. DCs (10 4 ) or PDCs (2 -3 × 10 4 ) were cultured with 10 5 DO11.10 CD4 + T cells. Cultures were pulsed after 72 h with 1 Ci of [H 3 ]thymidine, and incorporation was measured 16 h later.
IFN-␣ secretion assay. MACS-enriched splenic PDCs were cultured at 2 × 10 6 cells/ml in complete RPMI 1640 for 20 h, with 400 HAU/ml infl uenza virus A/Texas/1/77 (provided by R. Arnon, The Weizmann Institute, Rehovot, Israel). Supernatants were assayed using an IFN-␣ ELISA kit (Performance Biomedical Laboratories).
Conjugation of OVA to anti -mPDCA-1 F(ab ' ) 2 fragments and specifi city test. Anti -mPDCA-1 monoclonal antibody (rat IgG2b, ; Miltenyi Biotec GmbH) was digested with Pepsin A (Sigma-Aldrich). After size fractionation (Superdex 200 16/60 gel fi ltration column; GE Healthcare),
